title: Directed therapies in lung cancer: new hope?
abstract: Lung cancer (LC) is a serious health problem due to its high incidence and mortality. Surgery is the most effective therapeutic strategy in this type of tumor, but in recent years new drugs are being investigated that target specific components of the tumor cells, improving survival in patients with advanced disease and relapse. We present a review of individualized treatments in LC, particularly therapies that inhibit epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF) and anaplastic lymphoma kinase (ALK).
authors.affiliation: Servicio de Neumología, Complexo Hospitalario Universitario de Ourense, Ourense, Spain. parentelamelas@gmail.com
authors.forename: Isaura
authors.initials: I
authors.lastname: Parente Lamelas
authors.forename: José
authors.initials: J
authors.lastname: Abal Arca
authors.forename: José Luis
authors.initials: JL
authors.lastname: Fírvida Pérez
mesh_terms: D000077548:Anaplastic Lymphoma Kinase; D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D000918:Antibody Specificity; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000453:epidemiology / Q000601:surgery; D017326:Clinical Trials, Phase III as Topic; D003131:Combined Modality Therapy; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics; D005544:Forecasting; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000235:genetics / Q000601:surgery; D058990:Molecular Targeted Therapy; D015337:Multicenter Studies as Topic; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D015514:Oncogene Proteins, Fusion / Q000037:antagonists & inhibitors; D011446:Prospective Studies; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; C522504:EML4-ALK fusion protein, human; D009363:Neoplasm Proteins; D015514:Oncogene Proteins, Fusion; D047428:Protein Kinase Inhibitors; D042461:Vascular Endothelial Growth Factor A; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D066246:ErbB Receptors; D020794:Receptor Protein-Tyrosine Kinases